Quarterly report pursuant to Section 13 or 15(d)

OTHER RELATED PARTY TRANSACTIONS (Details Narrative)

v3.21.2
OTHER RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended
Jun. 15, 2021
Mar. 09, 2021
May 31, 2021
Mar. 31, 2021
Subsequent Event [Member] | William Horne [Member]        
Related Party Transaction [Line Items]        
Number of shares issued for services, value     $ 50,000  
Subsequent Event [Member] | IPO [Member] | Mr Ault [Member]        
Related Party Transaction [Line Items]        
Description of conversion     the effectiveness of the IPO, and in consideration for (i) the conversion of 750,000 shares of the Company’s Series A Preferred Shares beneficially owned by Mr. Ault through Ault Life Sciences, Inc. into 15,000,000 shares of Common Stock, (ii) the extension of the maturity date of the note in the original principal amount of $15,000,000 issued to the Company by Ault Life Sciences Fund, LLC, an entity controlled by Mr. Ault, to December 31, 2023, and (iii) the resignation by Mr. Ault as a director and executive officer of the Company  
Percentage of outstanding common shares     5.00%  
Digital Power Lending [Member] | IPO [Member]        
Related Party Transaction [Line Items]        
Number of shares sold (in shares) 2,000,000      
Securities Purchase Agreement [Member] | Digital Power Lending [Member]        
Related Party Transaction [Line Items]        
Number of shares sold (in shares)       6,666,667
Number of shares sold       $ 10,000,000
Description of related party transaction   DPL paid $4 million, less the $1.8 million in prior advances and the surrender for cancellation of a $50,000 convertible promissory note held by Ault Global Holdings, Inc (“Ault Global“), for an aggregate of 2,666,667 shares of Common Stock. Under the terms of the securities purchase agreement, DPL (i) purchased an additional 1,333,333 shares of Common Stock upon approval of the IND for Phase Ia clinical trials for AL001 for a purchase price of $2 million, and (ii) will purchase 2,666,667 shares of Common Stock upon the completion of these Phase Ia clinical trials for AL001 for a purchase price of $4 million    
Description of milestones       The Company further agreed to issue to DPL warrants to purchase a number of shares of Common Stock equal to 50% of the shares of Common Stock purchased under the securities purchase agreement at an exercise price of $3.00 per share. Finally, the Company agreed that for a period of 18 months following the date of the payment of the final tranche of $4 million, DPL will have the right to invest an additional $10 million on the same terms, except that no specific milestones have been determined with respect to the additional $10 million as of October 31, 2021
Consulting Agreement [Member] | Subsequent Event [Member] | IPO [Member] | Mr Ault [Member]        
Related Party Transaction [Line Items]        
Advisory and consulting services fees     $ 50,000